A randomized comparison of the efficacy and toxicity of epirubicin and doxorubicin in the treatment of patients with non-hodgkin's lymphoma
Open Access
- 1 June 1998
- Vol. 82 (11), 2282-2288
- https://doi.org/10.1002/(sici)1097-0142(19980601)82:11<2282::aid-cncr26>3.0.co;2-p
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin's lymphoma with MACOP-B: a Southwest Oncology Group study.Journal of Clinical Oncology, 1991
- Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas.Journal of Clinical Oncology, 1990
- Reduced Cardiotoxicity of Doxorubicin Delivered on a Weekly ScheduleAnnals of Internal Medicine, 1983
- Prospective evaluation of doxorubicin‐induced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomasCancer, 1983
- Efficacy and cost of cardiac monitoring in patients receiving doxorubicinCancer, 1982
- Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous InfusionAnnals of Internal Medicine, 1982
- Antitumor Activity of Anthracyclines: Experimental StudiesPublished by Springer Science and Business Media LLC ,1982
- The Anthracycline Antineoplastic DrugsNew England Journal of Medicine, 1981
- Doxorubicin Cardiotoxicity: Assessment of Late Left Ventricular Dysfunction By Radionuclide CineangiographyAnnals of Internal Medicine, 1981